Improvement in linear growth following GH therapy in young patients with PWS is well established based on a long history of randomized clinical trials [21–32] and registry/observational studies, resulting in GH becoming the standard of care for PWS [8, 33–37]. This evidence concerns the gene GH1 and Prader-Willi syndrome.